tiprankstipranks

Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs downgraded Rocket Pharmaceuticals (RCKT) to Sell from Neutral with a price target of $2, down from $13.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1